Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While the EXXUA launch is on track and has potential, the current financials show declining revenue, margins, and a net loss. The Q&A reveals mixed feedback on EXXUA prescriptions and no immediate plans for sales force expansion, indicating cautious optimism. The strong gross margin and stable cash reserves are positives, but the overall sentiment remains neutral due to financial weaknesses and uncertainties.
Key Financial Performance
ADHD net revenue $13.2 million, a slight decrease from the year-ago period and flat compared to Q1. The decrease is attributed to a broader deemphasis in marketing towards the ADHD portfolio due to the company's focus on EXXUA and the introduction of generic competition. This was partially offset by product price increases and improved gross-to-nets.
Pediatric portfolio net revenue $1.7 million, compared to $2.7 million last year and $715,000 in Q1. The decrease from the year-ago period is due to a deemphasis in marketing towards the pediatric portfolio in favor of EXXUA, particularly given FDA commentary around fluoride. The increase from Q1 is attributed to reduced quantity of returns and relative stabilization of prescriptions.
Net revenue $15.2 million, compared to $16.2 million in the prior year. The decrease is due to a shift in marketing focus towards EXXUA and reduced emphasis on the ADHD and pediatric portfolios.
Gross margin 63.5%, compared to 66.5% last year. The decrease is primarily due to a decrease in net revenue and transition-related expenses associated with the ADHD authorized generic performance, including a $600,000 inventory write-down. Excluding this write-down, gross margins would have been 67.4%.
Operating expenses (OpEx) $11.1 million, compared to $10.2 million in the prior year period. The increase is due to EXXUA launch investments, partially offset by improved operational efficiencies such as reduced facilities expense. This includes $300,000 in depreciation and stock compensation, with cash OpEx at $10.8 million.
Net loss $10.6 million, or $1.05 per share, compared to net income of $0.8 million, or $0.13 per share, in the prior year period. The loss was impacted by a derivative warrant liability loss of $8.2 million, compared to a gain of $3 million in the prior year, primarily related to changes in the company's stock price.
Adjusted EBITDA Negative $0.8 million, compared to positive $1.3 million in the prior year. The change is due to increased EXXUA launch investments and reduced marketing emphasis on the ADHD and pediatric portfolios, impacting net revenue and gross profits.
Cash and cash equivalents $30 million as of December 31, 2025, compared to $32.6 million at September 30, 2025. The decrease is attributed to normal operating procedures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of EXXUA: EXXUA, the first and only 5HT1a agonist approved by the FDA for the treatment of major depressive disorder (MDD), was commercially launched. It offers a novel and targeted approach to treating MDD, addressing unmet needs such as sexual dysfunction and weight gain associated with traditional antidepressants. Early feedback indicates good tolerability and patient satisfaction.
Market Expansion for EXXUA: EXXUA prescriptions have been written in 27 states, including areas without sales representatives. Over 100 doctors have prescribed EXXUA, and early refills are being observed. The product is supported by the Aytu RxConnect platform, ensuring broad patient access and predictable coverage.
Operational Efficiency in EXXUA Launch: The launch strategy includes a motivated sales team, virtual sales initiatives, and a rolling contract sales model. The RxConnect platform minimizes patient costs and administrative burdens, ensuring broad access. The company reduced its original launch investment budget from $10 million to under $8 million through efficient execution.
ADHD Portfolio Performance: ADHD net revenue was $13.2 million, slightly down from the prior year but stable sequentially. The introduction of an authorized generic for Adzenys has limited the impact of competition, with 85% of ADHD prescriptions dispensed through RxConnect.
Strategic Shift to Focus on EXXUA: The company is prioritizing resources towards EXXUA, deemphasizing its ADHD and pediatric portfolios. This shift aligns with the goal of addressing the significant unmet needs in MDD treatment.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
EXXUA Launch Challenges: The launch of EXXUA, a first-in-class treatment for major depressive disorder (MDD), faces challenges such as ensuring prescriber adoption, managing early access barriers, and achieving long-term brand growth. The company has implemented a no-cost guarantee for the first two months of therapy, which may delay revenue recognition until the third month.
ADHD Portfolio Risks: The ADHD portfolio is experiencing a decline in net revenue due to a shift in marketing focus towards EXXUA and the introduction of generic competition. The company expects continued transition from branded to generic products, which could impact revenue further.
Pediatric Portfolio Deprioritization: The pediatric portfolio has been deprioritized in favor of EXXUA, leading to reduced marketing efforts and a decline in net revenue. This deprioritization could impact the company's ability to maintain revenue from this segment.
Regulatory and Market Risks: The company faces regulatory challenges, such as the FDA's commentary on fluoride, which could impact the pediatric portfolio. Additionally, the broader market dynamics, including the need to manage costs and ensure compliance, pose ongoing risks.
Financial Risks: The company reported a net loss of $10.6 million for the quarter, driven by increased investments in the EXXUA launch and a decline in revenue from other portfolios. The reliance on EXXUA's success to offset these losses adds financial pressure.
Operational Risks: Operational risks include the need to efficiently manage the EXXUA launch while maintaining performance in other portfolios. The company must balance resources and ensure effective execution of its commercial strategy.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
EXXUA Launch Revenue Expectations: The company expects a small initial ramp in EXXUA net revenue for the March 2026 quarter due to deliberate efforts to remove early access barriers. This includes offering no-cost 14-day titration packs and guaranteeing full coverage for the first two months of therapy for commercially insured patients. Net revenue growth is expected to accelerate starting in the June 2026 quarter as these no-cost guarantees are removed.
Gross Margin Projections for EXXUA: Gross margins for EXXUA are expected to be approximately 69%, factoring in a 28% royalty and a true-up on cost of goods sold. Fixed expenses in cost of goods sold are anticipated, but upfront fees and milestone payments will be amortized to operating expenses.
Operational Expense Projections: Operational expenses for the March quarter are projected to increase to $4 million to $5 million, excluding depreciation and amortization. By the end of the fiscal year, the company expects a normalized quarterly run rate of $11.6 million, with $0.5 million in noncash expenses.
Breakeven Revenue Targets: The company estimates a breakeven point at $17.3 million of net revenue per quarter, including EXXUA-related expenses. Cash breakeven is projected at $16.6 million per quarter.
ADHD Portfolio Outlook: The ADHD portfolio is expected to experience some transition from branded to generic products. However, the company anticipates limited erosion within its RxConnect network and expects the portfolio to perform above standard expectations despite generic competition.
Pediatric Portfolio Focus: The pediatric portfolio remains noncore, with resources primarily focused on EXXUA. Future changes in FDA guidance may alter this approach.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What feedback has the sales team received from the 100 doctors who have written prescriptions?
A:The feedback is mixed, with motivations including addressing challenging patients who are not responding well to other treatments, side effects like sexual issues or weight gain, and interest in the new mechanism of action (MOA). The ease of prescribing through RxConnect also plays a role. Early prescriptions often involve difficult-to-treat patients, but over time, the product may be positioned earlier in treatment.
Q:Will there be a sales force expansion in fiscal '26, and what triggers would initiate it?
A:It is unexpected to expand the sales force quickly. Expansion will depend on overachieving internal forecasts and achieving cash flow. The company will not expand without cash on hand and Board approval. Profitability and cash flow are primary triggers, and there is no plan to raise capital for this purpose.
Q:What details can you provide about the direct-to-consumer campaign?
A:The campaign will be largely web-based, focusing on search engine optimization, keyword search campaigns, and exploring social media and forums like Reddit. The company will prioritize compliance with FDA regulations. The main focus remains on face-to-face sales interactions, with consumer campaigns being secondary until awareness among psychiatrists increases.
Q:Have there been delays or issues with prescriptions getting filled due to weather, and what is the mix of prescriptions filled through RxConnect versus retail pharmacies?
A:Weather has caused significant delays, impacting scripts getting filled, shipments to pharmacies, and sales reps' ability to meet doctors. Most prescriptions are being filled through RxConnect, but some are coming from retail pharmacies. The mix is largely commercial, with a heavier commercial split than the general market's 60-40 commercial-to-government ratio.
Q:Have supply issues caused by weather been resolved, and is there adequate supply to meet potential demand increases?
A:Yes, supply issues caused by weather have been resolved, with delays being only a few days. The company has adequate supply for the near term and beyond, with API and componentry stateside to scale production if demand exceeds forecasts.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the triggers for sales force expansion, using vague language about 'overachieving internal forecasts' and 'cash flow.' Similarly, the direct-to-consumer campaign details were broad, with no concrete plans or timelines provided.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adzenys
EXXUA approach
EXXUA launch
HTa receptor
Investor Day
KOL network
MDD Dr
adoption
adult
agonist HTa
antidepressant
availability
cash flow
change EXXUA
cognition
commentary
date
day
deemphasis marketing
disorder
dysfunction
efficacy
erosion
generic
implication
launch investment
need
practice
prescription RxConnect
therapy
tolerability
treatment MDD
volume
week
weight gain
AYTU Transcript
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals declining revenues in ADHD and Pediatric portfolios, a decrease in cash reserves, and a negative adjusted EBITDA. Although EXXUA's launch shows promise, the overall financial performance is weak. The Q&A session highlights potential but lacks concrete data, and management's responses were somewhat vague. Despite some positive anecdotes and potential for geographic expansion, the strategic shift and financial challenges overshadow these positives, leading to a negative sentiment.
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Unknown2-3
The earnings call presents a mixed picture. While the EXXUA launch is on track and has potential, the current financials show declining revenue, margins, and a net loss. The Q&A reveals mixed feedback on EXXUA prescriptions and no immediate plans for sales force expansion, indicating cautious optimism. The strong gross margin and stable cash reserves are positives, but the overall sentiment remains neutral due to financial weaknesses and uncertainties.
Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript
Unknown11-13
The earnings call summary presents mixed signals. Basic financials show decreased net revenue in some areas but improved gross margins. The EXXUA product development and market strategy are promising, but the guidance lacks clarity, and the Q&A reveals uncertainties in realignment and payer engagement. Despite a positive outlook for EXXUA, current financial health and lack of detailed guidance temper optimism, leading to a neutral sentiment.
Aytu BioPharma, Inc. (AYTU) Q4 2025 Earnings Call Transcript
Unknown9-23
The earnings call presents mixed signals: while there is positive growth in the pediatric portfolio and improved cash position, gross margins have decreased and net losses remain significant. The Q&A reveals strategic plans for future launches but also highlights potential uncertainties, like selective payer engagement. Overall, these factors balance out to a neutral sentiment, with no strong catalysts for a significant stock price movement in either direction.
AYTU Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
